All In Biotech

NDA 022064 · Chattem Sanofi

Xyzal

Levocetirizine Dihydrochloride · Oral

Priority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

May 25, 2007

Approved uses

2

Original approval plus efficacy supplements

Registered trials

77

22 Phase 3, 4 recruiting

FAERS reports

18,341

9,290 serious, 966 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2025.

XYZAL is a histamine H 1 -receptor antagonist indicated for: The relief of symptoms associated with perennial allergic rhinitis ( 1.1 ) The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria ( 1.2 ) 1.1 Perennial Allergic Rhinitis XYZAL is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. 1.2 Chronic Idiopathic Urticaria XYZAL is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older.

Mechanism: Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H 1 -receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs . 6 nmol/L, respectively). The clinical relevance of this finding is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XYZAL · LEVOCETIRIZINE DIHYDROCHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Levocetirizine Dihydrochloride" as an intervention, any sponsor and status, largest first.

All 77 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,535
  • fatigue1,340
  • headache1,232
  • pruritus1,204
  • nausea1,069
  • dyspnoea1,055
  • diarrhoea990
  • somnolence926
  • dizziness823
  • arthralgia781
  • cough764
  • rash758

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
200510
20066
200725
2008161
2009238
2010262
2011438
2012576
2013396
2014387
2015554
2016828
2017814
2018977
20191,693
20201,545
20211,240
20221,544
20231,669
20241,797
20251,800
20261,376

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Chattem Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.